T1	p 90 151	chemo-na?ve patients with advanced non-small cell lung cancer
T2	p 296 343	chemo-na?ve non-small cell lung cancer patients
T3	p 354 420	Patients with chemo-na?ve stage IIIB/IV non-small cell lung cancer
T4	p 677 728	A total of 80 patients were entered in this trial .
T5	i 62 73	gemcitabine
T6	i 83 86	S-1
T7	i 263 274	gemcitabine
T8	i 289 292	S-1
T9	i 488 491	S-1
T10	i 543 554	gemcitabine
T11	i 1243 1254	gemcitabine
T12	i 1259 1262	S-1
T13	o 208 216	efficacy
T14	o 221 227	safety
T15	o 769 782	response rate
T16	o 789 803	response rates
T17	o 882 907	time to treatment failure
T18	o 965 984	time to progression
T19	o 1042 1055	survival time
T20	o 1128 1144	toxicity profile
T21	o 1284 1292	feasible
T22	o 1297 1306	effective
T23	o 1409 1440	response rate and survival data